evitria specializes in CHO-based transient expression of recombinant proteins, with a focus on antibodies—including bispecific, Fc-silenced, and afucosylated formats. With over 100,000 transfections, we are a trusted partner for biotech and pharma worldwide.
Products, services, technology
Tailored CHO-based transient expression of recombinant proteins, specializing in antibodies: monoclonal, bispecific, Fc-silenced, and afucosylated. We deliver small to large-scale production for R&D, assay development, and preclinical applications.
Cooperation possibilities
We offer flexible, project-based collaborations—from pilot studies to high-throughput antibody production. Our team supports discovery to preclinical stages, providing tailored CHO-based expression services to meet your specific R&D needs.
Some insights
evitria accelerates biotherapeutic development by enabling rapid, reliable access to high-quality recombinant proteins. Our work supports breakthroughs in drug discovery, helping researchers bring life-changing treatments to patients faster.
We’re proud to be a trusted partner for global biotech and pharma, known for our reliability, scientific excellence, and customer focus. With 120,000+ CHO-based transfections, we empower innovation at every stage of therapeutic development.
We admire organizations that drive innovation with integrity—those advancing therapeutic frontiers while maintaining quality and patient focus. Role models include pioneers in antibody engineering, platform development, and open scientific collaboration.
Our team combines deep expertise in CHO-based protein expression, antibody engineering, and project execution. We aim to further expand our bioinformatics, automation, and data analytics capabilities to enhance speed, precision, and scalability.
“They help scientists make medicines.” It’s a simple summary—but true! At evitria, we support the creation of life-saving therapies by producing the proteins and antibodies researchers need to develop tomorrow’s treatments.
By fostering partnerships, talent development, and innovation-friendly regulations, the Swiss biotech ecosystem can help us expand our capabilities, stay at the forefront of antibody expression, and better support therapeutic discovery worldwide.
We welcome contact with biotech and pharma companies, CROs, academic researchers, and platform developers seeking a reliable partner for CHO-based recombinant protein and antibody expression across discovery and preclinical stages.